Design Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director Simeon George was granted 30,000 stock options in Design Therapeutics, Inc. with an exercise price of $10.55.
NASDAQ
John P. Schmid, a Director at Design Therapeutics, Inc., acquired 30,000 stock options with an exercise price of $10.55.
NASDAQ
Rodney W. Lappé, a Director at Design Therapeutics, Inc., acquired 30,000 stock options on June 9, 2026, as part of a pre-planned transaction.
NASDAQ
Design Therapeutics Director Justin D. Gover acquired 30,000 stock options with an exercise price of $10.55 on June 9, 2026.
NASDAQ
David Shapiro, a Director at Design Therapeutics, Inc., acquired 30,000 stock options.
NASDAQ
Heather A. Berger, a Director at Design Therapeutics, Inc., acquired 30,000 stock options with an exercise price of $10.55.
NASDAQ
Design Therapeutics Director David Shapiro was granted 67,500 stock options with an exercise price of $10.64, vesting over 12 to 36 months.
NASDAQ
Design Therapeutics' Chief Medical Officer, Chris Storgard, was granted 250,000 stock options with an exercise price of $9.1 per share, vesting over several years.
NASDAQ
Design Therapeutics, Inc. Chief Operating Officer Sean Jeffries was granted 375,000 stock options with an exercise price of $9.10, vesting over several years.
NASDAQ
Design Therapeutics, Inc. granted 150,000 stock options to Chief Accounting Officer Julie Burgess with an exercise price of $9.10 and a multi-year vesting schedule.
NASDAQ
Design Therapeutics Director Justin D. Gover was granted 45,000 stock options with a $9.1 exercise price, vesting over 36 months.
NASDAQ
Design Therapeutics, Inc. President, CEO, and Chairperson Pratik Shah was granted 750,000 stock options with a $9.1 exercise price.
NASDAQ
Design Therapeutics, Inc. President and CEO Pratik Shah's stock options for 295,312 shares vested after a key performance condition was met.
NASDAQ
Design Therapeutics Director Justin D. Gover was granted stock options for 45,833 shares with varying vesting schedules.
NASDAQ
A director at Design Therapeutics, Inc. sold 562,627 shares of common stock at $5.25 per share in a discretionary transaction.
NASDAQ
Design Therapeutics, Inc. Director William Arsani was granted 19,000 stock options with an exercise price of $4.01, vesting over 12 months starting June 10, 2025.
NASDAQ
Design Therapeutics, Inc. Director Heather A. Berger was granted 19,000 stock options with an exercise price of $4.01 per share, vesting over 12 months.
NASDAQ
John P. Schmid, a Director at Design Therapeutics, Inc. (DSGN), was granted 19,000 stock options with an exercise price of $4.01, vesting over 12 months.
NASDAQ
Rodney W. Lappe, a Director at Design Therapeutics, Inc., was granted 19,000 stock options with an exercise price of $4.01, vesting over 12 months.
NASDAQ
Simeon George, a Director and 10% Owner of Design Therapeutics, Inc., was granted 19,000 stock options with an exercise price of $4.01, vesting over 12 months.
NASDAQ
Design Therapeutics, Inc. Director Deepa Prasad was granted 19,000 stock options with an exercise price of $4.01, vesting over 12 months or by the next annual meeting.
NASDAQ
Design Therapeutics' Chief Medical Officer, Chris Storgard, was granted 400,000 stock options with an exercise price of $4.71, vesting over a four-year period.
NASDAQ
Rodney W. Lappe, a director at Design Therapeutics, acquired 25,993 stock options on January 2, 2025.
NASDAQ
Design Therapeutics' Chief Accounting Officer, Julie Burgess, was granted stock options for 135,000 shares on January 2, 2025.
NASDAQ
Design Therapeutics CEO, Pratik Shah, was granted 600,000 stock options with a $6.17 exercise price, vesting over a period of three years.
NASDAQ
Design Therapeutics' Chief Operating Officer, Sean Jeffries, was granted stock options for 260,000 shares on January 2, 2025.
NASDAQ
A Design Therapeutics director, Deepa Prasad, sold 3,806 shares of common stock at a price of $6.27 per share on December 18, 2024.
NASDAQ
Director William Arsani reported the sale of Design Therapeutics (DSGN) common stock on August 9, 2024.
NASDAQ
Director Simeon George acquired 19,000 stock options in Design Therapeutics, Inc. on June 13, 2024, at an exercise price of $3.82.
NASDAQ
Director William Arsani acquired stock options for 19,000 shares of Design Therapeutics, Inc. at an exercise price of $3.82 on June 13, 2024.